Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 8, 2009, Pages 667-674

  Fernlöf, Gunilla ^a   Sjöström, Britta M ^a   Lindell, Klas M ^a   Wall, Ulrika E ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anticoagulants; Antidotes; Haemorrhage; Oral direct thrombin inhibitor; Warfarin; Ximelagatran

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; FRESH FROZEN PLASMA; WARFARIN; XIMELAGATRAN;

ADULT; AGED; ANEURYSM RUPTURE; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRECIPITATE; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HALF LIFE TIME; HEART ATRIUM FIBRILLATION; HUMAN; LIVER DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; RETROSPECTIVE STUDY; THERAPY EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; BLOOD TRANSFUSION; DISEASE MANAGEMENT; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBIN; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 70449555472     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832ff5aa     Document Type: Article

References (29)

1. Olsson SB; Executive Steering Committee on behalf on the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362:1691-1698.
2. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, et al., SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 2005; 293:690-698.
3. Fiessinger J-N, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, et al., for the THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. JAMA 2005; 293:681-689. (Pubitemid 40216038)
4. Hirsch J, Guyatt G, Albers GW, Harrington R, Schünemann HJ. Executive summary: American College of Chest Physicians evidence-based clinical practice guideline. Chest 2008; 133:71-109.
5. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM, the Warfarin Reversal Consensus Group. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Austr 2004; 181:492-497.
6. Ansell J, Hirsch J, Poller L, Bussey H, Jacobson A, Hylek H. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126:204-233.
7. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4:1853-1863.
8. Stratmann G, DeSilva AM, Tseng EE, Hambleton J, Balea M, Romo AJ, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg 2004; 98:1635-1639.
9. Yee AJ, Kuter DJ. Successful recovery after an overdose of argatroban. Ann Pharmacother 2006; 40:336-339.
10. Ng HJ, Crowther MA. New antithrombotic agents: emphasis on hemorrhagic complications and their management. Semin Hematol 2006; 43 (suppl 1):S77-83.
11. Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis 2007; 18:547-553.
12. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008; 111:4871-4879.
13. Prandoni P, Tormene D, Perlati M, Brandolin B, Spiezia L. Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. Expert Opin Investig Drugs 2008; 17:773-777.
14. Savi P, Heault JP, Duchaussoy P, Millet L, Schaeffer P, Petitou M, et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008; 6:1697-1706.
15. Ma Q, Fareed J. Idraparinux sodium. Sanofi-Aventis. IDrugs 2004; 7:1028-1034.
16. Elg M, Carlsson S, Gustafsson D. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin Inhibitor in anesthesized rats and rabbits. Thromb Res 2001; 101:159-170.
17. Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001; 101:145-157.
18. Gruber A, Carlsson S, Kotze HF, Marzec U, Sarich TC, Hanson SR. Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates. Thromb Res 2007; 119:121-127.
19. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998; 9:119-128.
20. Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSevenTM) in healthy volunteers receiving acenocoumarol to an International Normalised Ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9:741-748.
21. Wolzt M, Levi M, Sarich TC, Boström SL, Eriksson UG, Eriksson-Lepkowska M, et al. Effect of recombinant factor VIIa on melagatraninduced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost 2004; 91:1090-1096.
22. Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin. Arch Intern Med 2006; 166:853-859.
23. Diener HC, Executive Steering Committee on behalf of the SPORTIF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation. Cerebrovasc Dis 2006; 21:279-293.
24. Haverkamp D, Hutten BA, Buller HR, Gallus AS, Lensing AW, Prins MH. The use of specific antidotes as a response to bleeding complications during anticoagulant therapy for venous thromboembolism. J Thromb Haemost 2003; 1:69-73.
25. Carlsson SC, Mattsson C, Eriksson UG, Sarich TC,Wahlander K, Eliasson A, et al. A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. Thromb Res 2005; 115:9-18.
26. Mattson C, Menschiek-Lundin A, Wa°hlander K, Lindahl TL. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromoplastin and the final dilution of the plasma sample. Thromb Haemost 2001; 86:611-615.
27. Kearon C, Johnston M, Moffat K, McGinnis J, Ginsberg JS. Effect of warfarin on activated thromboplastin time in patients receiving heparin. Arch Intern Med 1998; 158:1140-1143.
28. Baldi G, Altomonte F, Altomonte M, Ghirarduzzi A, Brusasco C, Parodi RC, et al. Intracranial haemorrhage in patients on antithrombotics: clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. Cerebrovasc Dis 2006; 22:286-293.
29. Pradaxa (dabigatran). Summary of product characteristics. 2008. Retrieved from http://www.emea.europa.eu.